TY - JOUR
T1 - Effects of covid-19 lockdown on tumour burden of melanoma and cutaneous squamous cell carcinoma
AU - Tejera-Vaquerizo, Antonio
AU - Paradela, Sabela
AU - Toll, Agustí
AU - Santos-Juanes, Jorge
AU - Jaka, Ane
AU - López, Alba
AU - Cañueto, Javier
AU - Bernal, Álvaro
AU - Villegas-Romero, Isabel
AU - Ferrándiz-Pulido, Carla
AU - Perandones, Héctor
AU - Moreno-Ramírez, David
AU - Domínguez-Mahamud, Carolina
AU - Salido-Vallejo, Rafael
AU - Sanmartín, Onofre
AU - Almazán-Fernández, Francisco M.
AU - Rodríguez-Jiménez, Pedro
AU - Bañuls, José
AU - Podlipnik, Sebastian
AU - Sandoval-Clavijo, Alejandra
AU - Boada, Aram
AU - García-Bracamonte, Beatriz
AU - Palencia, Sara
AU - Revilla-Nebreda, David
AU - Reola-Ramírez, Enara
AU - Gómez-Mateo, María Del Carmen
AU - Linares-Barrios, Mario
AU - Jiménez-Gallo, David
AU - González-Cruz, Carlos
AU - Samaniego, Elia
AU - Navedo-De Las Heras, María
AU - Taberner, Rosa
AU - Ródenas-Herranz, Teresa
AU - García-Donoso, Carmen
AU - Puig, Susana
AU - Nagore, Eduardo
N1 - Funding Information:
The current study was presented at the European Academy of Dermatology and Venereology (EADV) 2020 congress. Conflicts of interest: CG-D reports other from Lilly, grants and other from Novartis, outside the submitted work. SP reports grants and other from Amgen, personal fees and other from Avene, other from Abbvie, grants, personal fees, non-financial support and other from Almirall, personal fees from BSM, grants, personal fees and non-financial support from ISDIN, grants, personal fees and non-financial support from La Roche Posay, grants, personal fees and non-financial support from Leo Pharma, non-financial support from MSD, personal fees and non-financial support from Pierre Fabre, personal fees and non-financial support from Pfizer, personal fees, non-financial support and other from Regeneron, grants, personal fees and non-financial support from Roche, personal fees and non-financial support from Sanofi, grants and personal fees from Sunpharma, grants from Castle, personal fees from Canfield, non-financial support from Lilly, non-financial support from Novartis, grants from Melagenix, outside the submitted work.
Funding Information:
The authors thank M. A. Descalzo-Gallego from the Research Unit of the Spanish Academy of Dermatology and Venereology (AEDV) for reviewing the study methodology and statistical analyses, and the pathology laboratories at the different hospitals for helping to identify cases. Reviewed and approved by Hospital Reina Sof?a de C?rdoba IRB; approval #4682. The current study was presented at the European Academy of Dermatology and Venereology (EADV) 2020 congress.
Publisher Copyright:
© 2021, Medical Journals/Acta D-V. All rights reserved.
PY - 2021
Y1 - 2021
N2 - The aim of this study was to compare tumour burden in patients who underwent surgery for melanoma and cutaneous squamous cell carcinoma during nation-wide lockdown in Spain due to COVID-19 (for the period 14 March to 13 June 2020) and during the same dates in 2019 before the COVID-19 pandemic. In ad-dition, associations between median tumour burden (Breslow thickness for melanoma and maximum clinical diameter for cutaneous squamous cell carcinoma) and demographic, clinical, and medical factors were analysed, building a multivariate linear regression model. During the 3 months of lockdown, there was a significant decrease in skin tumours operated on (41% decrease for melanoma (n = 352 vs n = 207) and 44% decrease for cutaneous squamous cell carcinoma (n = 770 vs n = 429)) compared with the previous year. The proportion of large skin tumours operated on increased. Fear of SARS-CoV-2 infection, with re-spect to family member/close contact, and detection of the lesion by the patient or doctor, were related to thicker melanomas; and fear of being diagnosed with cancer, and detection of the lesion by the patient or relatives, were related to larger size cutaneous squa-mous cell carcinoma. In conclusion, lockdown due to COVID-19 has resulted in a reduction in treatment of skin cancer.
AB - The aim of this study was to compare tumour burden in patients who underwent surgery for melanoma and cutaneous squamous cell carcinoma during nation-wide lockdown in Spain due to COVID-19 (for the period 14 March to 13 June 2020) and during the same dates in 2019 before the COVID-19 pandemic. In ad-dition, associations between median tumour burden (Breslow thickness for melanoma and maximum clinical diameter for cutaneous squamous cell carcinoma) and demographic, clinical, and medical factors were analysed, building a multivariate linear regression model. During the 3 months of lockdown, there was a significant decrease in skin tumours operated on (41% decrease for melanoma (n = 352 vs n = 207) and 44% decrease for cutaneous squamous cell carcinoma (n = 770 vs n = 429)) compared with the previous year. The proportion of large skin tumours operated on increased. Fear of SARS-CoV-2 infection, with re-spect to family member/close contact, and detection of the lesion by the patient or doctor, were related to thicker melanomas; and fear of being diagnosed with cancer, and detection of the lesion by the patient or relatives, were related to larger size cutaneous squa-mous cell carcinoma. In conclusion, lockdown due to COVID-19 has resulted in a reduction in treatment of skin cancer.
KW - COVID-19
KW - Cutaneous squamous cell carcinoma
KW - Delay
KW - Melanoma
KW - SARS-CoV-2
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85115040280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115040280&partnerID=8YFLogxK
U2 - 10.2340/00015555-3890
DO - 10.2340/00015555-3890
M3 - Article
C2 - 34396424
AN - SCOPUS:85115040280
SN - 0001-5555
VL - 101
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
IS - 8
M1 - adv00525
ER -